

08  
522 298

**PREVENTION OF HYPERPHOSPHATEMIA**  
**IN KIDNEY DISORDER PATIENTS**

**Abstract of the Disclosure**

5       The 19-nor-vitamin D analogs, and particularly 19-nor-  
1 $\alpha$ ,25-dihydroxyvitamin D<sub>2</sub>, possess low calcemic and  
phosphatemic activity while also having the ability to suppress  
parathyroid hormone (PTH) production. The suppressive effect  
on PTH secretion of these 19-nor analogs without significant  
changes in serum calcium or serum phosphorus make them  
10       ideal tools for the treatment of secondary hyperparathyroidism  
in patients having kidney disorders.